AMN Q2 2026 Results Signal Recovery, Validate Deep Value Thesis

What happened

AMN Healthcare reported Q2 2026 revenue of $673 million and adjusted EBITDA of $73 million, marking the first year-over-year quarterly revenue increase since its post-pandemic downturn and exceeding typical trough estimates. The results align with management’s stabilization-to-growth narrative, driven by low-single-digit Nurse & Allied gains and early contributions from higher-margin international nurse and VMS lines. Adjusted EPS of $0.77 and GAAP income of $0.53 reflect improved operating leverage as cost actions and top-line recovery take hold. The quarter provides concrete evidence that the cyclical bottom has passed and that AMN’s mix shift toward technology-enabled workforce solutions is beginning to bear fruit. With volumes, bill rates, and margins all showing sequential improvement, the company’s turnaround thesis gains credibility, though sustained execution and credit metrics remain key watchpoints.

Implication

Over 12–24 months, if AMN sustains low-single-digit revenue growth and gross margins above 27%, adjusted EBITDA could expand 30–50% from 2025 trough levels, compressing EV/EBITDA toward the low teens and supporting a share price of $22–24. Improved capital allocation and debt reduction would further de-risk the story, though a failure to maintain volume and spread momentum or a Kaiser relationship loss could still pressure the stock. The Q2 print meaningfully lowers the probability of the $12 bear case, reinforcing a patient accumulation stance, but investors should monitor credit rating actions and the sustainability of international nurse and VMS growth.

Thesis delta

The Q2 2026 results directly validate the core assumption that AMN’s nurse and allied demand has transitioned from declines to growth, with achieved margins and earnings providing tangible evidence of stabilization. This report increases conviction in the base and bull cases, as the company demonstrates it can execute on its mix-shift strategy, and reduces the likelihood of a relapse into deeper earnings erosion, though full recovery is still early.